Vynleads (VYND) 10-Q 22 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 22, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	333-227499
Entity Registrant Name	Vynleads, Inc.
Entity Central Index Key	0001745078
Entity Tax Identification Number	47-4584272
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	596 Herrons Ferry Road
Entity Address, Address Line Two	Suite 301
Entity Address, City or Town	Rock Hill
Entity Address, State or Province	SC
Entity Address, Postal Zip Code	29730
City Area Code	(845)
Local Phone Number	745-0981
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,599,830

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 2,257	$ 7,229
Accounts Receivable		635
Holdback Receivable from merchant, net of reserve for refunds of $59 and $42, respectively	15,763	16,929
Prepaid Expenses and other current assets	3,831	13,206
Total current assets	21,851	37,999
Total assets	21,851	37,999
Current Liabilities:
Accounts payable and accrued expenses	275,489	256,784
Notes Payable	180,000	122,575
Notes Payable - Related Party	15,000
Total current liabilities	470,489	379,359
Notes Payable, net of current		8,925
Total liabilities	470,489	388,284
Commitments and contingencies (See Note 6)
Stockholders' deficit:
Preferred stock; $0.0001 par value; 5,000,000 shares authorized, no shares issued and outstanding, respectively
Common stock; $0.0001 par value; 50,000,000 shares authorized; 11,599,830 shares and 11,599,830 shares issued and outstanding, respectively	1,160	1,160
Additional paid-in capital	1,461,752	1,364,252
Accumulated deficit	(1,911,550)	(1,715,697)
Total stockholders' deficit	(448,638)	(350,285)
Total liabilities and stockholders' deficit	$ 21,851	$ 37,999

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Refunds	$ 59	$ 42
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	11,599,830	11,599,830
Common stock, shares outstanding	11,599,830	11,599,830

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue, net of refunds and chargebacks		$ 8,379	$ 484	$ 47,492
Cost and Expenses:
Cost of Revenue	8,717	13,104	25,084	52,866
Advertising		71		1,885
Selling, general and administrative expense	45,394	88,844	169,546	266,767
Total costs and expenses	54,111	102,019	194,630	321,518
Loss from operations	(54,111)	(93,640)	(194,146)	(274,026)
Other income	6,500		6,500	2,000
Interest expense	(2,480)	(2,063)	(8,207)	(5,990)
Net loss before provision for income taxes	(50,091)	(95,703)	(195,853)	(278,016)
Provision for income taxes				(1,555)
Net loss	$ (50,091)	$ (95,703)	$ (195,853)	$ (279,571)
Net loss per common share, basic and diluted	$ 0	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average common shares outstanding, basic and diluted	11,599,830	11,491,498	11,595,285	11,520,252

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 1,140	$ 1,199,565	$ (1,336,067)	$ (135,362)
Beginning balance, shares at Dec. 31, 2019	11,399,830
Stock-based compensation		56		56
Net Loss			(70,512)	(70,512)
Ending balance, value at Mar. 31, 2020	$ 1,140	1,199,621	(1,406,579)	(205,818)
Ending balance, shares at Mar. 31, 2020	11,399,830
Stock-based compensation		56		56
Common Stock Issued for Services	$ 20	44,980		45,000
Common Stock Issued for Services, shares	200,000
Net Loss			(113,356)	(113,356)
Ending balance, value at Jun. 30, 2020	$ 1,160	1,244,657	(1,519,935)	(274,118)
Ending balance, shares at Jun. 30, 2020	11,599,830
Stock-based compensation		56		56
Capital Contribution		84,943		84,943
Net Loss			(95,703)	(95,703)
Ending balance, value at Sep. 30, 2020	$ 1,160	1,329,656	(1,615,638)	(284,822)
Ending balance, shares at Sep. 30, 2020	11,599,830
Beginning balance, value at Dec. 31, 2020	$ 1,160	1,364,252	(1,715,697)	(350,285)
Beginning balance, shares at Dec. 31, 2020	11,599,830
In Kind Contribution of Services		32,500		32,500
Net Loss			(75,458)	(75,458)
Ending balance, value at Mar. 31, 2021	$ 1,160	1,396,752	(1,791,155)	(393,243)
Ending balance, shares at Mar. 31, 2021	11,599,830
In Kind Contribution of Services		32,500		32,500
Net Loss			(70,304)	(70,304)
Ending balance, value at Jun. 30, 2021	$ 1,160	1,429,252	(1,861,459)	(431,047)
Ending balance, shares at Jun. 30, 2021	11,599,830
In Kind Contribution of Services		32,500		32,500
Net Loss			(50,091)	(50,091)
Ending balance, value at Sep. 30, 2021	$ 1,160	$ 1,461,752	$ (1,911,550)	$ (448,638)
Ending balance, shares at Sep. 30, 2021	11,599,830

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (195,853)	$ (279,571)
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities
Stock-based compensation		28,293
Capital contribution from CEO's salary	97,500	84,943
PPP Courtesy Credit	(6,500)
Changes in operating assets and liabilities and other, net	29,881	76,422
Net cash flows used in operating activities	(74,972)	(89,913)
Cash flows from financing activities:
Proceeds from notes payable - Related Party	15,000
Proceeds from notes payable	55,000	27,000
Net cash flows provided by financing activities	70,000	27,000
Net decrease in cash	(4,972)	(62,913)
Cash at beginning of period	7,229	63,395
Cash at end of period	2,257	482
Supplemental disclosure of cash flow information:
Income taxes paid		1,555
Interest paid		4,460
Supplemental for non-cash investing and financing activities:
Stock issued for prepaid consulting		$ 16,875

Business

Business	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	1. Business Vynleads, Inc. (“Vynleads”) was incorporated as a Delaware corporation on July 15, 2015. We are a provider of health and wellness information principally targeted to people who have prediabetes or type 2 diabetes. We provide information to our customers who are seeking to make healthy choices by providing clear, generic blueprints, education, resources, and support. Our core product is our proprietary Lifestyle Blueprint, a digital guide that provides dietary recommendations for a very low calorie eight-week diet together with information focusing on what, how and how much a person eats, nutritional information and how a person’s body does and does not use food to enable our customers to continue leading a more successful lifestyle. We also offer nutritional supplements and monthly subscriptions to our proprietary newsletter which covers a wide variety of healthy living-related topics. Our corporate headquarters are located in Rock Hill, South Carolina.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. Going Concern Our unaudited three months ended 50,091 95,703 During the nine months ended September 30, 2021 and 2020, we have reported a net loss of $ 195,853 and $ 279,571 . 448,638 1,911,550 Despite our current sales, expense, cash flow projections, and aggregate cash and holdback 15,763 The COVID-19 pandemic has materially and adversely impacted the U.S. economy and financial markets, with legislative and regulatory responses including unprecedented monetary and fiscal policy actions across all sectors, and there is significant uncertainty as to timing of stabilization and recovery. The extent of the COVID-19 impacts will depend on future actions and outcomes, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the outbreak, the short-term and long-term economic impact of the outbreak (including the effect on advertising activity, consumer discretionary spending and our employees), and the actions taken to mitigate the impact of the virus, and the pace of economic and financial market recovery when the COVID-19 pandemic subsides, among others. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate adverse effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for the remainder of fiscal year 2021. Our ability to meet our current and projected obligations depends on our ability to generate sufficient sales and to control expenses and will require that we seek additional capital through private and/or public financing sources. There can be no assurances that we will achieve our forecasted financial results or that we will be able to raise additional capital to operate our business. Any such failure would have a material adverse impact on our liquidity and financial condition and could force us to curtail or discontinue operations entirely and could require us to file for protection under bankruptcy laws. These conditions raise substantial doubt as to our ability to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Accounting Principles The accompanying unaudited condensed financial statements (the “Financial Statements”) of Vynleads, Inc. (the “Company,” “we,” “us” or “our”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and, therefore, do not include all information and footnotes required by GAAP for complete financial statements. In our opinion, the Financial Statements contain all adjustments of a normal recurring nature necessary to present fairly our financial position as of September 30, 2021 and the results of our operations and cash flows for the three and nine months and months Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining the valuation of our reserve for refunds, our holdback reserve, the fair value-based measurement of stock-based compensation, accruals and the estimated useful life of intangible assets. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements. Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value. Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for refunds, which reserve is $ 59 42 Revenue Recognition The Company accounts for revenue in accordance with Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for the three and nine months Percentage of Revenue by Type Three months ended Nine months ended September 30, September 30, (unaudited) (unaudited) 2021 2020 2021 2020 Internet content subscriptions 0.0 % 10.8 % 0.0 % 7.7 % Nutritional supplements 100.0 % 89.2 % 100.0 % 92.3 % Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue. Advertising Costs Advertising costs for the three months ended September 30, 2021 and 2020 0 71 0 1,885 Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766 Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense. Stock-Based Compensation Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. The valuation of employee stock options is an inherently subjective process, since market values are generally not available for long-term, non-transferable employee stock options. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value. The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends. Expected Volatility. Risk-Free Interest Rate. Expected Term. Stock Option Exercise Price and Grant Date Price of Common Stock. We are required to estimate the level of award forfeitures expected to occur and record compensation expense only for those awards that are ultimately expected to vest. This requirement applies to all awards that are not yet vested. Due to the limited number of unvested options outstanding, the majority of which are held by executives and members of our Board of Directors, we have estimated a zero forfeiture rate. We will revisit this assumption periodically and as changes in the composition of the option pool dictate. Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820-10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. The carrying amounts of our cash, holdback receivable, prepaid expenses, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of September 30, 2021 and December 31, 2020. Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to us.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions 15,000 5% due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 406 During the three months ended September 30, 2021 and 2020, we paid Mr. Bezusov $ 0 0 0 2,000 On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. Mr. Mannine’s compensation includes a grant of 10 100,000 0.225 On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. During the three months and nine month ended September 30, 2021, $ 32,500 97,500 On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2020, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed until May 2022. As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including: · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions.

Notes Payable and Notes Payable

Notes Payable and Notes Payable – Related Party	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Notes Payable and Notes Payable – Related Party	5. Notes Payable and Notes Payable – Related Party On August 4, 2021, the Company executed a note payable to an individual in the amount of $ 15,000 , interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 117 On May 10, 2021, the Company executed a note payable to an individual in the amount of $ 20,000 5% due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 392 On April 15, 2021, the Company executed a note payable to an individual in the amount of $ 10,000 5% due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 230 On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $ 15,000 5% due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 406 On February 3, 2021, the Company executed a note payable to an individual in the amount of $ 10,000 5% due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 327 400 On December 17, 2020, the Company executed a note payable to an individual in the amount of $ 19,500 5% due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 767 40 On October 27, 2020, the Company executed a note payable to an individual in the amount of $ 10,000 5% due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 463 90 On May 5, 2020, the Company received loan proceeds in the amount of $ 27,000 The loan matures on April 20, 2022 and bears an interest rate of 1.00% 6,500 20,500 3,433 On November 18, 2019, the Company executed a note payable to an individual in the amount of $ 50,000 5% due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. $1,250 3,421 1,510 On November 18, 2019, the Company executed a note payable to an individual in the amount of $ 25,000 5% 2,336 1,380

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Employment Agreement On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. The initial term of the agreement expires in June 2023, subject to successive automatic one- year renewals unless a non-renewal notice is received by either party at least 90 days prior to the expiration of the then current renewal term. Mr. Mannine’s compensation includes: · an annual base salary of $ 130,000 · an annual bonus as determined by the board of directors; · a grant of 10 100,000 0.225 · participation in all benefit plans we may offer our employees; and · 20 paid vacation days annually. · if we should terminate Mr. Mannine’s employment without “cause” or if he should resign for “good reason" or if a “change of control” occurs, we are obligated to pay him a lump-sum severance payment equal to the sum of three months’ base salary, plus one month for every year he was employed and 50% of three years annual bonus (based on the prior year’s compensation); · if Mr. Mannine’s employment is terminated as a result of his death or disability, he is entitled to receive his base salary and a pro-rata annual bonus, if any, based on the year during which such termination is effective; or · if we should terminate Mr. Mannine for “cause,” or if he voluntarily terminates the agreement, he is entitled to receive his base salary only through the date of termination, and he is not be entitled to any other compensation for the calendar year during which the termination occurs or any subsequent calendar period, including, but not limited to, any annual bonus, if any, that has not already been paid. The employment agreement with Mr. Mannine contains customary confidentiality, non-compete and indemnification clauses. 32,500 97,500 Commitments On March 8, 2018, we entered into an advisory agreement with a scientific advisor to provide certain services to us. Pursuant to the agreement, we issued 100,000 0.90 100,000 1,905 We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $ 0.225 45%; 2.63% 5 During the three months ended September 30, 2021 and related to the warrants 0 56 and related to the warrants 0 168 On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2020, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed until May 2022. · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions. On February 12, 2020, we entered a consulting agreement with Primoris Group Inc (“Primoris”). Primoris was issued 200,000 45,000 0.225 100,000 Under terms of the consulting agreement, we agree to pay Primoris $ 8,000 96,000 84,000 Contingencies In April 2016, we entered into a Promotion and Royalty Agreement (the “Agreement”) with a consultant to obtain certain promotional services from him (the “Promoter”), including the use of his name and appearance. In consideration for the services rendered by the Promoter, we agreed to use commercially reasonable efforts to promote and sell a book authored by him (the “Book”) and to pay him a percentage of the sales of the Book after deductions for all direct costs of fulfilling such sales (the “Royalty”). During the course of 2017, the Promoter initiated a series of informal claims and filed unauthorized uniform commercial code financing statements (“UCC Liens”) in several states as liens against us and certain of our officers, directors, and founders, alleging non-payment for the Royalty amounts due under the Agreement. We dispute the Promoter’s claims and have determined that any and all amounts due to the Promoter under the Agreement have been paid in full. We have succeeded in removing certain of the UCC Liens and are pursuing action to remove the remaining unauthorized UCC Liens. We do not believe that the claims of the Promoter are valid in any respect.

Concentration of Credit Risk an

Concentration of Credit Risk and Major Customers and Suppliers	9 Months Ended
	Sep. 30, 2021
Risks and Uncertainties [Abstract]
Concentration of Credit Risk and Major Customers and Suppliers	7. Concentration of Credit Risk and Major Customers and Suppliers None of our revenues are concentrated with any single customer composing 10% or more of our total revenues. We purchase our inventory of herbal/natural supplements from one supplier. While we believe that we will be able to find a secondary supplier, there could be a manufacturing delay in the transition to a new supplier and such a supply interruption would materially impact our business for some period of time.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders’ Equity	8. Stockholders’ Equity Our authorized capital stock consists of 50,000,000 0.0001 5,000,000 0.0001 11,599,830 11,599,830 no In-kind Contribution of Service On September 21, 2020, Mr. Mannine voluntarily agreed to cancel his employment agreement and waive all cash due and any related accruals. During the three and nine months ended September 30, 2021, $ 32,500 97,500 Consulting Agreement 200,000 45,000 0.225 100,000 Preferred Stock Our board of directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and other matters. Our board of directors may authorize the issuance of preferred stock, which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our board of directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of our common stock to be effective while any shares of preferred stock are outstanding. Warrants On October 10, 2017, we entered into the Financing Agreement with CRG. In connection with the related equity financing as of December 31, 2017, CRG had earned 368,111 0.225 34,405 0.225 45%; 2.2% 5 During January 2018, as part of the Private Placement more fully described in Note 4, CRG earned an additional 17,655 0.225 $1,670 0.225 45%; 2.51% 5 100,000 0.90 September 30, 2021 100,000 0.225 45%; 2.63% 5 During the three months ended September 30, 2021 and 2020, we have recorded stock-based compensation expense of $ 0 56 and related to the warrants 0 168 As of September 30, 2021 and December 31, 2020, the intrinsic value for warrants outstanding and exercisable is $ 109,943 144,662 The following table summarizes information about the warrants earned and outstanding as of September 30, 2021 and December 31, 2020: Warrants Earned and Outstanding September 30, 2021 December 31, 2020 (unaudited) Weighted Weighted Average Average Exercise Exercise Warrants Price Warrants Price Outstanding, beginning of period 485,766 $ 0.364 485,766 $ 0.364 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of period 485,766 $ 0.364 485,766 $ 0.364 Exercisable, end of period 485,766 $ 0.364 485,766 $ 0.364 As of September 30, 2021 (unaudited) Warrants Outstanding and Exercisable by Range of Exercise Price Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 0.90 485,766 1.36 $ 0.364 485,766 $ 0.364 Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 0.90 485,766 2.1 $ 0.364 485,766 $ 0.364

Stock Option Plan

Stock Option Plan	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock Option Plan	9. Stock Option Plan In December 2017 our board of directors adopted our 2017 Equity Incentive Plan, or the “2017 Plan.” Our stockholders ratified the 2017 Plan in December 2017. The purpose of the 2017 Plan is to encourage ownership in our company by our officers, directors, employees and consultants, and to incentivize and align the interests of the plan participants with the interests of our stockholders. We have reserved 1,100,000 1,000,000 The board of directors or a committee of the board of directors administers the 2017 Plan. Presently, the 2017 Plan is administered by our board of directors. The term of each plan option and the manner in which it may be exercised is determined by the board of directors or a committee of the board of directors, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant. The terms of grants or any other type of award under the plan are determined by the board of directors or committee of the board of directors at the time of grant. The 2017 Plan provides that the maximum value of any award during any calendar year cannot exceed $1,000,000. Generally, options which are exercisable at the date of the plan participant’s termination from our employment or severance of the relationship with our company must be exercised within three months of the termination date; the plan administrator may extend the exercise period of the option for a separated plan participant providing that the extended date does not go beyond the original expiration date of the option. Similarly, generally options which are exercisable at the date of the plan participant’s disability or death must be exercised within six months of the termination date in the event of the disability of the plan participant or 12 months following the plan participant’s death. In our discretion, any outstanding options held by a plan participant terminated for cause may be immediately cancelled. In the event there is a “change in control” of our company as defined in the 2017 Plan, as determined by the board of directors or the committee, we may in our discretion: i) provide for the assumption or substitution of, or adjustment (including to the number and type of shares and exercise or purchase price applicable) to, each outstanding award; ii) accelerate the vesting of options and terminate any restrictions on stock awards; and/or iii) provide for termination of awards as a result of the change in control on such terms and conditions as it deems appropriate, including providing for the cancellation of awards for a cash or other payment to the participant. The number of shares of our common stock underlying any outstanding but unexercised option and the exercise price of that option will be proportionally adjusted in the event of a stock split, stock combinations, dividends, and similar corporate events. On June 14, 2018, pursuant to the employment agreement with Mr. Mannine, more fully described in Note 6 100,000 0.225 13,221 45%; 2.2% 10 No three and nine months ended September 30, 2021 and 2020. As of September 30, 2021 and December 31, 2020, the intrinsic value for options outstanding and exercisable is $ 28,500 37,500 The following table summarizes information about stock options outstanding and exercisable as of as of September 30, 2021 and December 31, 2020: Summary of Information Regarding about Stock Options Outstanding and Exercisable September 30, 2021 December 31, 2020 (unaudited) Weighted Weighted Average Average Exercise Exercise Options Price Options Price Outstanding, beginning of period 100,000 $ 0.225 100,000 $ 0.225 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of period 100,000 $ 0.225 100,000 $ 0.225 Exercisable, end of period 100,000 $ 0.225 100,000 $ 0.225 Options available for future grant, end of year 1,000,000 1,000,000 As of September 30, 2021 (unaudited) Options Outstanding by Exercise Price Range Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 100,000 7.18 $ 0.225 100,000 $ 0.225 As of December 31, 2020 Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 100,000 7.93 $ 0.225 100,000 $ 0.225

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Event	10. Subsequent Event On September 28, 2021, the Company executed a note payable to an individual in the amount of $ 50,000 5% due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. The funds were received in October 2021. On November 19, 2021, the Company fully repaid a $ 10,000 400

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Use of Accounting Estimates	Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining the valuation of our reserve for refunds, our holdback reserve, the fair value-based measurement of stock-based compensation, accruals and the estimated useful life of intangible assets. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements.
Cash	Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value.
Holdback Receivable	Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for refunds, which reserve is $ 59 42
Revenue Recognition	Revenue Recognition The Company accounts for revenue in accordance with Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for the three and nine months Percentage of Revenue by Type Three months ended Nine months ended September 30, September 30, (unaudited) (unaudited) 2021 2020 2021 2020 Internet content subscriptions 0.0 % 10.8 % 0.0 % 7.7 % Nutritional supplements 100.0 % 89.2 % 100.0 % 92.3 % Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue.
Advertising Costs	Advertising Costs Advertising costs for the three months ended September 30, 2021 and 2020 0 71 0 1,885
Loss Per Share	Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766
Income Taxes	Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. The valuation of employee stock options is an inherently subjective process, since market values are generally not available for long-term, non-transferable employee stock options. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value. The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends. Expected Volatility. Risk-Free Interest Rate. Expected Term. Stock Option Exercise Price and Grant Date Price of Common Stock. We are required to estimate the level of award forfeitures expected to occur and record compensation expense only for those awards that are ultimately expected to vest. This requirement applies to all awards that are not yet vested. Due to the limited number of unvested options outstanding, the majority of which are held by executives and members of our Board of Directors, we have estimated a zero forfeiture rate. We will revisit this assumption periodically and as changes in the composition of the option pool dictate.
Fair Value of Financial Instruments	Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820-10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. The carrying amounts of our cash, holdback receivable, prepaid expenses, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of September 30, 2021 and December 31, 2020.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to us.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Percentage of Revenue by Type	Percentage of Revenue by Type Three months ended Nine months ended September 30, September 30, (unaudited) (unaudited) 2021 2020 2021 2020 Internet content subscriptions 0.0 % 10.8 % 0.0 % 7.7 % Nutritional supplements 100.0 % 89.2 % 100.0 % 92.3 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Warrants Earned and Outstanding	Warrants Earned and Outstanding September 30, 2021 December 31, 2020 (unaudited) Weighted Weighted Average Average Exercise Exercise Warrants Price Warrants Price Outstanding, beginning of period 485,766 $ 0.364 485,766 $ 0.364 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of period 485,766 $ 0.364 485,766 $ 0.364 Exercisable, end of period 485,766 $ 0.364 485,766 $ 0.364
Warrants Outstanding and Exercisable by Range of Exercise Price	Warrants Outstanding and Exercisable by Range of Exercise Price Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 0.90 485,766 1.36 $ 0.364 485,766 $ 0.364 Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 0.90 485,766 2.1 $ 0.364 485,766 $ 0.364

Stock Option Plan (Tables)

Stock Option Plan (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of Information Regarding about Stock Options Outstanding and Exercisable	Summary of Information Regarding about Stock Options Outstanding and Exercisable September 30, 2021 December 31, 2020 (unaudited) Weighted Weighted Average Average Exercise Exercise Options Price Options Price Outstanding, beginning of period 100,000 $ 0.225 100,000 $ 0.225 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of period 100,000 $ 0.225 100,000 $ 0.225 Exercisable, end of period 100,000 $ 0.225 100,000 $ 0.225 Options available for future grant, end of year 1,000,000 1,000,000
Options Outstanding by Exercise Price Range	Options Outstanding by Exercise Price Range Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 100,000 7.18 $ 0.225 100,000 $ 0.225 As of December 31, 2020 Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 100,000 7.93 $ 0.225 100,000 $ 0.225

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ 50,091	$ 95,703	$ 195,853	$ 279,571
[custom:WorkingCapitalDeficit-0]	448,638		448,638
Retained Earnings (Accumulated Deficit)	1,911,550		1,911,550		$ 1,715,697
Holdback Receivable from merchant, net of reserve for refunds	$ 15,763		$ 15,763		$ 16,929

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Percentage of Revenue by Type) (Details) - Revenue, Product and Service Benchmark [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Internet Content Subscriptions [Member]
Product Information [Line Items]
Percentage of revenues	0.00%	10.80%	0.00%	7.70%
Nutritional Supplements [Member]
Product Information [Line Items]
Percentage of revenues	100.00%	89.20%	100.00%	92.30%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Accounting Policies [Abstract]
Refunds	$ 59		$ 59		$ 42
Advertising	$ 0	$ 71	$ 0	$ 1,885
Potentially dilutive shares	585,766	585,766	585,766	585,766

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 14, 2018	Mar. 16, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Options issued
Exercise price
In-kind Contribution of Service			$ 32,500		$ 97,500
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Consulting fees			0	$ 0	0	$ 2,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Expected term	10 years
Options issued	100,000
Exercise price	$ 0.225
Note Payable [Member] | Mr Sergei Stetsenko [Member]
Related Party Transaction [Line Items]
Note payable		$ 15,000
Interest rate		5.00%
Term		due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Accrued interest			$ 406		$ 406

Notes Payable and Notes Payab_2

Notes Payable and Notes Payable – Related Party (Details Narrative) - USD ($)

Aug. 04, 2021

May 10, 2021

Apr. 05, 2021

Feb. 03, 2021

May 14, 2020

May 05, 2020

Nov. 18, 2019

Nov. 19, 2021

Oct. 31, 2021

Mar. 16, 2021

Dec. 17, 2020

Oct. 27, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2020

Short-term Debt [Line Items]

Interest paid

$ 4,460

PPP Courtesy Credit

6,500

Note Payable Nine [Member]

Short-term Debt [Line Items]

Note payable

$ 15,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

117

Note Payable One [Member]

Short-term Debt [Line Items]

Note payable

$ 20,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

392

Note Payable Two [Member]

Short-term Debt [Line Items]

Note payable

$ 10,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

230

Note Payable Three [Member]

Short-term Debt [Line Items]

Note payable

$ 15,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

406

Note Payable Four [Member]

Short-term Debt [Line Items]

Note payable

$ 10,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

327

Interest paid

$ 400

Note Payable Five [Member]

Short-term Debt [Line Items]

Note payable

$ 19,500

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

767

$ 40

Note Payable Six [Member]

Short-term Debt [Line Items]

Note payable

$ 10,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

463

90

P P P Loan [Member]

Short-term Debt [Line Items]

Note payable

$ 20,500

Interest rate

1.00%

Term

The loan matures on April 20, 2022 and bears an interest rate of

Proceeds from Loans

$ 27,000

Debt Instrument, Periodic Payment

$ 3,433

Note Payable Seven [Member]

Short-term Debt [Line Items]

Note payable

$ 50,000

Interest rate

5.00%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

3,421

1,510

Accrued interest paid

$ 1,250

Note Payable Eight [Member]

Short-term Debt [Line Items]

Note payable

$ 25,000

Interest rate

5.00%

Accrued interest

$ 2,336

$ 1,380

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 12, 2020	Jun. 14, 2018	Mar. 08, 2018	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued
Exercise price
In-kind Contribution of Service				$ 32,500		$ 97,500
Stock-based compensation				0	$ 56	0	$ 168
Payable in advance						$ 15,000
Scientific Advisor [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life			5 years
Issued			100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.90
Vested						100,000		100,000
Fair value			$ 1,905
Offering price			$ 0.225
Volatility			45.00%
Risk free interest rate			2.63%
Primoris Group Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value	$ 45,000
Offering price	$ 0.225
Common stock issued	200,000
Payable in advance						$ 8,000
Accrued expense				$ 96,000		$ 96,000		$ 84,000
Primoris Group Inc [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested	100,000
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual base salary		$ 130,000
Expected life		10 years
Options issued		100,000
Exercise price		$ 0.225
Volatility		45.00%
Risk free interest rate		2.20%

Stockholders' Equity (Informati

Stockholders' Equity (Information About Warrants Earned and Outstanding) (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning of period	485,766	485,766
Outstanding, beginning of period	$ 0.364	$ 0.364
Granted
Granted
Exercised
Exercised
Forfeited
Forfeited
Expired
Expired
Outstanding, end of period	485,766	485,766
Outstanding, end of period	$ 0.364	$ 0.364
Exercisable, end of period	485,766	485,766
Exercisable, end of period	$ 0.364	$ 0.364

Stockholders' Equity (Warrants

Stockholders' Equity (Warrants Outstanding by Price Range) (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	$ 0.225	$ 0.225
Range of exercise price, upper limit	$ 0.90	$ 0.90
Number outstanding	485,766	485,766
Remaining Average Contractual Life	1 year 4 months 9 days	2 years 1 month 6 days
Weighted Average Exercise Price, Outstanding	$ 0.364	$ 0.364
Number exercisable	485,766	485,766
Weighted average exercise price, exercisable	$ 0.364	$ 0.364

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Feb. 12, 2020	Mar. 08, 2018	Oct. 10, 2017	Jan. 31, 2018	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized					50,000,000		50,000,000		50,000,000
Common stock, par value					$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized					5,000,000		5,000,000		5,000,000
Preferred stock, par value					$ 0.0001		$ 0.0001		$ 0.0001
Common stock, shares issued					11,599,830		11,599,830		11,599,830
Common stock, shares outstanding					11,599,830		11,599,830		11,599,830
Preferred stock, share issued					0		0		0
Preferred stock, shares outstanding					0		0		0
In-kind Contribution of Service					$ 32,500		$ 97,500
Stock-based compensation					0	$ 56	0	$ 168
Intrinsic value for warrants outstanding					$ 109,943		$ 109,943		$ 144,662
Primoris Group Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued	200,000
Fair value	$ 45,000
Offering price	$ 0.225
Primoris Group Inc [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested	100,000
C R G Finance A G [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value			$ 34,405	$ 1,670
Offering price			$ 0.225	$ 0.225
Issued			368,111	17,655
Exercise price			$ 0.225	$ 0.225
Volatility			45.00%	45.00%
Risk free interest rate			2.20%	2.51%
Expected life			5 years	5 years
Scientific Advisor [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value		$ 1,905
Offering price		$ 0.225
Vested							100,000		100,000
Issued		100,000
Exercise price		$ 0.90
Volatility		45.00%
Risk free interest rate		2.63%
Expected life		5 years

Stock Option Plan (Stock Option

Stock Option Plan (Stock Options Outstanding) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Outstanding, beginning of period	100,000	100,000
Outstanding, beginning of period	$ 0.225	$ 0.225
Granted
Granted
Exercised
Exercised
Forfeited
Forfeited
Expired
Expired
Outstanding, end of period	100,000	100,000
Outstanding, end of period	$ 0.225	$ 0.225
Exercisable, end of period	100,000	100,000
Exercisable	$ 0.225	$ 0.225

Stock Option Plan (Stock Opti_2

Stock Option Plan (Stock Options Outstanding by Exercise Price) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Range of Exercise Price, lower	$ 0.225	$ 0.225
Range of Exercise Price, upper	$ 0.225	$ 0.225
Number Outstanding	100,000	100,000
Remaining Average Contractual Life	7 years 2 months 4 days	7 years 11 months 4 days
Weighted Average Exercise Price	$ 0.225	$ 0.225
Number Exercisable	100,000	100,000
Exercisable Weighted Average Exercise Price	$ 0.225	$ 0.225

Stock Option Plan (Details Narr

Stock Option Plan (Details Narrative) - USD ($)	Jun. 14, 2018	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Total awards reserved		1,100,000
Common stock reserved		1,000,000		1,000,000
Options issued
Exercise price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 28,500		$ 37,500
Chief Executive Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Options issued	100,000
Exercise price	$ 0.225
Options fair value	$ 13,221
Expected volatility	45.00%
Risk free rate	2.20%
Expected term	10 years
Stock option expense		$ 0	$ 0

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - USD ($)	Feb. 03, 2021	Nov. 19, 2021	Sep. 28, 2021	Sep. 30, 2021	Sep. 30, 2020
Subsequent Event [Line Items]
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 4,460
Note Payable Four [Member]
Subsequent Event [Line Items]
Note payable	$ 10,000
Interest rate	5.00%
Term	due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Repayments of notes payable		$ 10,000
Interest Paid, Excluding Capitalized Interest, Operating Activities		$ 400
Subsequent Event [Member]
Subsequent Event [Line Items]
Note payable			$ 50,000
Interest rate			5.00%
Term			due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.